切换导航
关闭
  • 菜单
  • Setting

Zalcitabine

扎西他滨
Catalog No.
B2223
逆转录酶抑制剂
组合的产品项目
规格价格库存 数量
10mM (in 1mL DMSO)
¥ 454.00
现货
50mg
¥ 409.00
现货
100mg
¥ 590.00
现货

电话: 021-55669583

邮箱: sales@apexbio.cn

全球经销商

A

背景

Zalcitabine is a nucleoside analog reverse transcriptase inhibitor (NRTI).

化学属性

Physical AppearanceA solid
StorageStore at -20°C
M.Wt211.22
Cas No.7481-89-2
FormulaC9H13N3O3
Solubilityinsoluble in EtOH; ≥10.65 mg/mL in DMSO with gentle warming; ≥15.87 mg/mL in H2O with ultrasonic
Chemical Name4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
SDFDownload SDF
Canonical SMILESC1CC(OC1CO)N2C=CC(=NC2=O)N
运输条件 蓝冰运输或根据您的需求运输。
一般建议不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

试验操作

Cell experiment:[1]

Cell lines

3201 (feline lymphoid) cells, 81C (sarcoma-positive, leukemia-negative feline lung fibroblast) cells, and primary feline bone marrow cells

Reaction Conditions

0 ~ 384 μM zalcitabine

Applications

Zalcitabine (5 ~ 10 μM) inhibited feline leukemia virus (FeLV) infection of feline lymphoid cells by greater than 80%, while 6.07 ~ 12.13 μM zalcitabine was required to similarly inhibit infection of feline fibroblasts. However, 43 ~ 384 μM zalcitabine was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%.

Animal experiment:[1]

Animal models

Cats challenged intravenously with FeLV 1 ~ 3 days after drug treatment began

Dosage form

22, 15, 10, and 5 mg/kg per h

Administered by continuous intravenous infusion for 28 days

Applications

Doses of 22 and 15 mg/kg per h were extremely toxic, causing death in 8 of 10 cats. The 10 mg/kg per h dose was slightly toxic, causing chronic progressive thrombocytopenia over the 28-day treatment period. Of 10 cats given 10 or 5 mg of zalcitabine per kg per h, only one was completely protected from FeLV antigenemia. However, conversion to positive FeLV antigenemia status was delayed by 2 ~ 7 weeks in seven of nine remaining animals.

Note

The technical data provided above is for reference only.

References:

1. Polas PJ, Swenson CL, Sams R, et al. In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrobial Agents and Chemotherapy, 1990, 34(7): 1414-1421.

质量控制